Yet another company has fallen into the purgatory that is the FDA Complete Response Letter (CRL) cycle. While it was not altogether unexpected that MannKind (Nasdaq:MNKD) would get another CRL from the FDA (which is tantamount to a rejection), this nitpicky rejection from the agency will likely set the company back at least another year in its attempt to get inhaled insulin to the market and in the hands of diabetics.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

The Latest Developments
On Wednesday afternoon, MannKind announced that the FDA had sent the company a CRL for its most recent re-application for its Afrezza inhaled insulin. This time the FDA's concerns were about potential differences between the MedTone inhaler used in past pivotal studies and the next-generation device that the company intends to actually launch with approval.

The FDA has now determined that the company needs to run at least two additional new studies (one in Type 1 diabetics and one in Type 2 diabetics) to determine if all of the relevant data is equivalent between the two devices. The FDA also wants at least one arm of one of the studies to include patients using the older MedTone device so that there can be head-to-head comparisons. (For related reading, check out The Curious And Complicated Case Of MannKind.)

To some extent, this is a legitimate request from the FDA. It is fair for the agency to want to confirm that the two devices work in basically the same fashion and produce the same outcomes in patients. Moreover, the FDA's request that the study include at least 12 weeks of consistent use (after a titration period) is not terribly onerous either - after all, diabetes drug studies often run at least a year, and the FDA increasingly seems to be demanding a minimum of two years of data.

In addition to the head-to-head comparison, the FDA wants more mundane data like information on the new device, updated safety information and so forth. (For more, see Dark Days In Diabetes.)

Will The FDA Be Reasonable?
Whether or not MannKind management foresaw the need for this data to deal with the FDA or launch the device commercially, the company had already begun two studies (Affinity 1 and 2) to test the next-gen device. The company stated that it intends to go to the FDA and see if they can modify these existing studies to include a MedTone arm and therefore meet the FDA's new requirements.

In a reasonable and rational world, the FDA would go along with this, even though the FDA is loathe to approve any "midstream" changes to a trial's protocol. But does anybody want to bet on the FDA being rational and reasonable?

The Future For MannKind
Even if the FDA is willing to cut the company a small break and modify the Affinity studies, it is likely going to take at least six months to run the study, and then additional time to collect the data and submit a new NDA to the FDA. At that point, the clock starts all over again and it could take upwards of a year for the FDA to render another verdict. If MannKind is very, very lucky, this might delay Afrezza by a year (assuming the data is to the FDA's liking), but 18 months up to two years may be more likely.

In the meantime, this is clearly not going to help the company's partnering efforts. Assuming that there was Big Pharma interest in Afrezza (and that may be more of an "if" than MNKD bulls want to believe), why wouldn't they either wait or press MannKind for more favorable terms? After all, Merck (NYSE:MRK), Sanofi (NYSE:SNY) and Novartis (NYSE:NVS) didn't get to be large companies by being pushovers at the negotiating table.

As MannKind stews, this is incrementally positive news for high-flying NovoNordisk (NYSE:NVO) and its NovoRapid insulin - a product that would be at some considerable risk given the very promising pharmokinetics of Afrezza insulin. While the same is true for other rapid-acting insulin-makers like Sanofi and Lilly (NYSE:LLY), the incremental impact is a bit less. Likewise, this could give investors in Biodel (Nasdaq:BIOD) a bit more hope as the company won't be as far behind MannKind in dealing with its own FDA rejection and new trials.

The Bottom Line
MannKind was always a risky stock, and Wednesday's events are just par for the course. While it may well be true that the FDA is being finicky and demanding past a point of reasonable diligence, the fact is that MannKind has to deal with the FDA that is, not the FDA that should be. Though I do not see how there is much argument left about whether Afrezza is an advance in the care of diabetes (it is), getting through the FDA minefield is just one step, and the even bigger minefield of the commercial market (and the true demand for inhaled insulin) still awaits. (For related reading, check out Icahn's Largest Positions.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Fortinet: A Great Play on Cybersecurity

    Discover how a healthy product mix, large-business deal growth and the boom of the cybersecurity industry are all driving Fortinet profits.
  2. Stock Analysis

    2 Catalysts Driving Intrexon to All-Time Highs

    Examine some of the main reasons for Intrexon stock tripling in price between 2014 and 2015, and consider the company's future prospects.
  3. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  4. Charts & Patterns

    Understand How Square Works before the IPO

    Square is reported to have filed for an IPO. For interested investors wondering how the company makes money, Investopedia takes a look at its business.
  5. Technical Indicators

    4 Ways to Find a Penny Stock Worth Millions

    Thinking of trading in risky penny stocks? Use this checklist to find bargains, not scams.
  6. Personal Finance

    Protect Your Home From Medicaid Liens

    Plan ahead for long-term care needs to protect your home and your estate.
  7. Professionals

    Chinese Slowdown Affects Iron Ore Market

    The Chinese economy's ongoing slowdown is having a major impact on iron ore demand.
  8. Investing Basics

    Why do Debt to Equity Ratios Vary From Industry to Industry?

    Obtain a better understanding of the debt/equity ratio, and learn why this fundamental financial metric varies significantly between industries.
  9. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  10. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  6. Net Present Value - NPV

    The difference between the present values of cash inflows and ...
  1. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>
  6. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!